Icecure Medical ICCM 深 沪
等待开盘 11-05 09:30:00 美东时间
0.7906
+0.020
+2.54%
华盛通- 最 高0.8101
- 今 开0.81
- 成交量 4.69万股
- 最 低 0.7775
- 昨 收 0.771
- 总市值 270.92万
- 52周最高 22.50
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 0.75
- 委 比 84.70%
- 总股本 342.67万
- 历史最高 365.009
- 量 比 0.63
- 振 幅 4.23%
- 历史最低 0.75
- 每 手 1
- 风险率 7.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IceCure Medical Shareholders Approve Agenda After Quorum Delay
Icecure Medical ( ($ICCM) ) has issued an announcement. IceCure Medical Ltd. is...
11-03 05:29
IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer
First patient enrolled and treated at West Cancer Center in Tennessee, USA CAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as...
10-27 20:40
Full Transcript: Icecure Medical Q2 2026 Earnings Call
Icecure Medical (NASDAQ:ICCM) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access the full call...
09-18 19:09
IceCure Medical Inks Distribution Agreement With Scovas Medical To Distribute IceCure's ProSense Cryoablation Systems In Netherlands
IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agre...
08-24 19:51
IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastas...
08-13 21:14
Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.40) by 2.14 percent. This is a 23.89 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $889.000 thousa...
08-12 21:36
IceCure Medical Announces That The Society Of Interventional Oncology Submitted A Petition To The National Comprehensive Cancer Network Breast Cancer Guidelines Panel To Include Percutaneous Cryoablation Without Surgical Excision As An Option For Breast Cancer
IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Society of Interventional Oncology ("SIO") has submitted a fo...
07-29 20:30
